Novel Peptide-drug Conjugate Melflufen Efficiently Eradicates Bortezomib-resistant Multiple Myeloma Cells Including Tumor-initiating Myeloma Progenitor Cells-Reference-Cited by-同舟云学术

Novel Peptide-drug Conjugate Melflufen Efficiently Eradicates Bortezomib-resistant Multiple Myeloma Cells Including Tumor-initiating Myeloma Progenitor Cells

Published:2021-06-12 Issue:7 Volume:5 Page:e602
ISSN:2572-9241
Container-title:HemaSphere
language:en
Short-container-title:

Author:

Byrgazov Konstantin,Besse Andrej,Kraus Marianne,Slipicevic Ana,Lehmann Fredrik,Driessen Christoph,Besse Lenka

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Hematology

Reference54 articles.

1. Multiple myeloma: diagnosis and treatment.;Rajkumar;Mayo Clin Proc,2016

2. Bortezomib for the treatment of hematologic malignancies: 15 years later.;Robak;Drugs R D,2019

3. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1.;Rajkumar;Blood,2011

4. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study.;Kumar;Leukemia,2012

5. Proteasome inhibitors: an expanding army attacking a unique target.;Kisselev;Chem Biol,2012

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The emerging role of melflufen and peptide-conjugates in multiple myeloma;Current Opinion in Oncology;2024-08-22

2. A review: FDA-approved fluorine-containing small molecules from 2015 to 2022;European Journal of Medicinal Chemistry;2023-11

3. Pharmacokinetics and Metabolism of Melflufen, an Alkylating Peptide–Drug Conjugate, in Patients with Relapsed Refractory Multiple Myeloma;The Journal of Clinical Pharmacology;2023-10-20

4. ANCHOR: melflufen plus dexamethasone and daratumumab or bortezomib in relapsed/refractory multiple myeloma—final results of a phase I/IIa study;Haematologica;2023-08-31

5. Revisiting the role of alkylating agents in multiple myeloma: Up-to-date evidence and future perspectives;Critical Reviews in Oncology/Hematology;2023-07